NCT01305941View on ClinicalTrials.gov

A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

August 31, 2016

Study Completion Date

October 16, 2017

Conditions
HER-2 Positive Breast Cancer
Interventions
DRUG

Everolimus

everolimus 5 mg PO daily as two 2.5-mg tablets

DRUG

Vinorelbine

vinorelbine 25 mg/m2 will be administered via IV infusion over 6-10 minutes weekly.

DRUG

Trastuzumab

2 mg/kg IV administered over 30 minutes weekly

Trial Locations (4)

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

28203

Carolinas Healthcare System, Charlotte

35294

University Of Alabama at Birmingham, Birmingham

37212

Vanderbilt-Ingram Cancer Center, Nashville

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

UNC Lineberger Comprehensive Cancer Center

OTHER